OssDsign AB (SE:OSSD)
:OSSD
Top Page
OssDsign AB
(OSSD)
Select Model
Select Model
Rating:47Neutral
Price Target:
kr3.50
▼(-69.03% Downside)
Action:ReiteratedDate:04/11/26
The score is held back primarily by persistent cash burn and continued operating/net losses despite strong revenue growth and very high gross margins. Technicals are also weak with the stock far below major moving averages and negative momentum. Valuation is constrained by losses (negative P/E) and the absence of dividend support.
Positive Factors
Revenue Growth
Rapid, sustained revenue acceleration indicates growing clinical adoption and expanding market penetration for OssDsign's implants. Durable top-line growth supports scaling of sales channels, validates product-market fit, and creates optionality to invest in commercialization and clinical evidence that can underpin long-term profitability if operating spend is controlled.
Negative Factors
Persistent Operating Losses
Sustained negative EBIT margins mean core operations are not yet profitable, forcing reliance on external capital. Over time persistent losses can erode equity, constrain strategic choices, and require either faster margin improvement or continued funding; without durable operating profitability, long-term shareholder value remains at risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Rapid, sustained revenue acceleration indicates growing clinical adoption and expanding market penetration for OssDsign's implants. Durable top-line growth supports scaling of sales channels, validates product-market fit, and creates optionality to invest in commercialization and clinical evidence that can underpin long-term profitability if operating spend is controlled.
Read all positive factors
OssDsign AB (OSSD) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr637.21M
Dividend YieldN/A
Average Volume (3M)297.02K
Price to Earnings (P/E)―
Beta (1Y)-0.50
Revenue Growth38.43%
EPS Growth57.76%
CountrySE
Employees32
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.20
Shares Outstanding110,625,916
10 Day Avg. Volume325,245
30 Day Avg. Volume297,022
Financial Highlights & Ratios
PEG Ratio3.07
Price to Book (P/B)4.04
Price to Sales (P/S)6.95
P/FCF Ratio-17.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.31
Revenue Forecast (FY)kr214.54M
OssDsign AB Business Overview & Revenue Model
Company Description
OssDsign AB (publ) designs, manufactures, and sells implants and material technology for bone regeneration in Sweden, Germany, the United States, the United Kingdom, rest of Europe, and internationally. The company's products include OSSDSIGN cran...
How the Company Makes Money
OssDsign AB generates revenue through the sale of its proprietary medical implants and bone graft products to hospitals, clinics, and healthcare providers globally. The company leverages direct sales channels in some regions and also collaborates ...
OssDsign AB Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
78
Positive
Cash Flow
34
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 180.16M | 133.94M | 112.16M | 56.98M | 31.73M |
| Gross Profit | 173.47M | 127.75M | 83.64M | 45.13M | 20.84M |
| EBITDA | -46.76M | -45.31M | -122.02M | -89.41M | -79.97M |
| Net Income | -50.99M | -49.66M | -130.49M | -99.39M | -93.92M |
Balance Sheet | |||||
| Total Assets | 397.87M | 307.42M | 356.39M | 339.50M | 343.99M |
| Cash, Cash Equivalents and Short-Term Investments | 191.35M | 100.86M | 165.94M | 124.65M | 151.37M |
| Total Debt | 1.37M | 1.97M | 3.15M | 13.60M | 14.13M |
| Total Liabilities | 87.84M | 93.36M | 105.26M | 91.39M | 81.26M |
| Stockholders Equity | 310.03M | 214.06M | 251.13M | 248.11M | 262.72M |
Cash Flow | |||||
| Free Cash Flow | -71.43M | -63.04M | -94.03M | -89.36M | -89.84M |
| Operating Cash Flow | -64.03M | -62.38M | -93.91M | -89.23M | -89.78M |
| Investing Cash Flow | -7.40M | -657.00K | -124.00K | -129.00K | -51.85M |
| Financing Cash Flow | 163.18M | -2.46M | 135.40M | 61.84M | 243.43M |
OssDsign AB Technical Analysis
Negative
11.30
Price Trends
6.31
Negative
8.63
Negative
11.44
Negative
Market Momentum
-0.34
Positive
17.16
Positive
4.94
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:OSSD, the sentiment is Negative. The current price of 11.3 is above the 20-day moving average (MA) of 5.97, above the 50-day MA of 6.31, and below the 200-day MA of 11.44, indicating a bearish trend. The MACD of -0.34 indicates Positive momentum. The RSI at 17.16 is Positive, neither overbought nor oversold. The STOCH value of 4.94 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:OSSD.
OssDsign AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | kr1.07B | -74.03 | -4.20% | ― | 21.71% | -80.37% | |
55 Neutral | kr915.08M | 168.74 | 6.93% | ― | -5.80% | -65.99% | |
52 Neutral | kr719.26M | -5.78 | -36.55% | ― | 62.24% | 21.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | kr637.21M | -24.57 | ― | ― | 38.43% | 57.76% | |
46 Neutral | kr588.74M | 13.94 | -2.52% | ― | -8.10% | 62.08% | |
44 Neutral | kr921.85M | -17.24 | -4.42% | ― | 13.48% | 28.98% |
* Healthcare Sector Average
SE:OSSD
OssDsign AB
3.50
-10.58
-75.14%
SE:PAX
Paxman AB
46.10
-15.90
-25.65%
SE:SEZI
Senzime AB
4.58
0.89
24.15%
SE:BACTI.B
Bactiguard Holding AB
16.80
-14.90
-47.00%
SE:CRAD.B
C-Rad AB Class B
27.10
-1.70
-5.90%
SE:SEDANA
Sedana Medical AB
9.28
1.03
12.48%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.